Type II (non-insulin-dependent) diabetes mellitus has been considered to be a polygene disorder [1] . Although several gene mutations have been found in the patients with Type II diabetes [2±8] including maturity onset diabetes of the young (MODY) [5, 9±12], the main susceptibility genes that are common to different ethnic backgrounds have not been identified. On the other hand, reduced insulin secretion is a pathophysiological characteristic observed in nonobese patients with Type II diabetes. Among proteins related to insulin secretion in the islet beta cells, we focused on syntaxin 1A, one of the SNAP receptor (SNARE) proteins [13] , which is expressed in the islet beta cells [14, 15] , because insulin secretion from islet cells has been reported to be inhibited by the anti-syntaxin 1 antibodies [16] . It has also been reported that expression of syntaxin 1A in the isolated islets of GK rats ± a putative animal model for nonobese Type II diabetes ± was reduced, and that restoration of its expression by the recombinant adenovirus-mediated gene transduction system improved the impaired insulin secretion [17] . These findings suggest that the syntaxin 1A plays a functional role in the process of insulin secretion and is a candidate gene for Type II diabetes. Thus, we identified and Diabetologia (2001) 
characterized gene encoding syntaxin 1A and screened the gene for mutations in Japanese Type II diabetic patients.
Materials and methods
Characterization for coding exons of syntaxin 1A gene. Human syntaxin 1A gene was cloned from bacterial artificial chromosome (Genome System, St Louis, Mo., USA) by polymerase chain reaction (PCR) using primers designated with reference to the sequence of cDNA (GenBank ACC No. L37 792). The positions of exon-intron junctions were determined by comparison with the sequence of cDNA [18] and the GT-AG rule.
Subjects and mutation analysis. We enrolled 182 unrelated Japanese Type II diabetic patients without severe obesity (body mass index less than 30 kg/m 2 ) ( Table 1 ) and 181 nondiabetic subjects without a family history of diabetes mellitus. Type II diabetic patients with early onset (under 25 years of age) and late onset (over 56 years of age) were excluded. All patients had had diabetes for longer than 3 years. Patients whose insulin treatment started within 3 years after onset were excluded. Anti-GAD antibodies were measured using radioimmunoassay kit based on recombinant human GAD65 (Cosmic corporation, Tokyo, Japan) in all patients treated with insulin or sulfonylureas and the patients carrying the antibodies were excluded. Non-diabetic subjects were over 60 years of age and without severe obesity and were confirmed to have fasting plasma glucose of less than 6.1 mmol/l and HbA 1 c less than 5.8 %. Informed consent was obtained from all participants. The study was approved by the Ethical Committee of Wakayama University of Medical Science and was in accordance with the principle of the Declaration of Helsinki. Genomic DNA was extracted from peripheral leukocyte. All newly identified 10 coding exons of the syntaxin 1A gene were amplified by PCR using the primers shown (Table 2), and were directly sequenced by dideoxy chain termination method using ABI Prism 310 (PE Biosystem Japan, Tokyo, Japan).
In the analysis of clinical characteristics, the age at onset refers to the age of diagnosis of diabetes mellitus.
Statistical analysis. Data is shown as means SEM. Categorical variables were compared by chi-square analysis or Fisher's extraction test. Differences between continuous variables were evaluated by Student's t test. Multiple regression analysis was used to find out the independent association between genotype status (CC vs CT + TT) of the SNP (D68D) in syntaxin 1A gene and clinical characteristics [gender, age at onset, BMI, duration of the disease, and mode of treatment (insulin treatment)]. A p value of less than 0.05 was considered to be statistically significant.
Results
Structure of the gene and mutation screening. The syntaxin 1A gene spread around 10 kb and composed of at least 10 exons (Fig. 1, Table 3 ). Mutation screening showed that there were three single nucleotide polymorphisms (SNPs); silent mutation [D68D, GAT to GAC (T to C)] in the exon 3, T to C at 52 bp down stream from the 3' end of the exon 7, and G to A at 93 bp upstream from the 5' end of exon 8. Genotype frequencies of these SNPs were the statistically consistent in Hardy-Weinberg equilibrium. The allele frequencies of these SNPs were almost same between patients with Type II diabetes and patients without diabetes. However, in the SNP of exon 3 (D68D, T to C), genotype frequency of the homozygote of C allele (CC) was higher in the diabetic group than in the non-diabetic group, and the difference showed marginal significance [TT, TC and CC were 41.76 %, 41.76 % and 16.48 % in Type II diabetic group (n = 182) and 34.8 %, 54.12 % and 11.05 % in the non-diabetic group (n = 181), respectively (p = 0.0499)]. 
Numbers of exons are tentative SNP (D68D, T to C) and clinical parameters in Type II diabetic patients. Diabetic patients were divided into two subgroups according to the genotype of the SNP in D68D, CC and other genotypes (TT and TC), and clinical parameters were compared between these subgroups ( Table 4 ). The age of onset in the patients with the CC genotype was significantly lower than in the patients with the other genotypes. This influenced the marked difference of age between the two subgroups because duration of diabetes in each subgroup was almost same. Multiple regression analysis confirmed that the CC genotype was strongly and independently associated with the onset age (Table 5) . Patients with the CC genotype had a trend of higher frequency of insulin treatment than patients with the other genotypes in all diabetic patients and a significance was obtained when diabetic patients who had diabetes for 10 years or longer were analysed (Table 4) . Although there was no significant association between genotype status of the SNP and insulin therapy when evaluated by multiple regression analysis using all patients, a significant association was obtained when patients who had had diabetes for 10 years or more were analysed ( Table 5) .
The number of insulin-treated patients in each subgroup was compared every 5 years after onset of the disease (Fig. 2) . Patients with the CC genotype had insulin treatment more frequently than patients with the other genotypes at every point and showed significance at 10 years The sites at which introns interrupt the mRNA and protein sequences are indicated. Exon sequences are in capital letters and intron sequences are in lowercase letters. The sizes of introns were estimated by restriction mapping. Numbers of exons are tentative. In insulin-treated patients, the time from the onset of diabetes to the start of the insulin therapy was shorter in patients with the CC genotype, but not significantly, than in patients with the other genotype ( Table 4) . By contrast, the daily dosage of injected insulin in patients with the CC genotype was significantly lower than of that in the others (Table 4 ).
Discussion
We found that the Syntaxin 1A gene consists of 10 coding exons spanning 10 kb, a finding different from a previous study reporting (GenBank Acc No. U87310, U87312, U87314, and U87 315) 7 coding exons for the gene. These new exons and their flanking introns have no serious mutations that might affect the function as far as we know. Three SNPs existed in this region. Among these, the frequency of the CC genotype in the SNP of D68D (T to C) was significantly higher in Type II diabetic patients than in non-diabetic subjects although it showed marginal significance. The CC genotype also influenced the clinical factors of Type II diabetic patients such as age of onset of the disease and the number of insulin-treated patients. Thus, although syntaxin 1A might not be a main susceptibility gene for Type II diabetes, the CC genotype of the SNP, D68D is one of a predisposing marker for Type II diabetes.
Our findings that patients carrying the CC genotype had a higher frequency of insulin treatment (Table 4 and 5) indicate that the SNP is one of genetic markers affecting the insulin requirement in Type II diabetic patients. However, the power of this SNP might be weak and reveals itself only in patients who have had diabetes for a long time, because the significant association was obtained when patients with a short duration of diabetes (less than 10 years) were excluded (Table 4 and 5). Consistent with these results, significant differences were obtained at 10 and 15 years when we compared the frequency of insulin treatment in patients with the CC genotype and patients with other genotypes chronologically (every 5 years) (Fig. 2) . In general, Type II diabetic patients Table 4 . Comparison of clinical characteristics according to the SNP (D68D, T to C) of the human syntaxin 1A gene in Type II diabetic patients All patients (n = 182)
Patients with duration of 10 years or more (n = 147) do not require insulin treatment, especially in the early stages. However, insulin treatment is required with much high frequency in the Type II diabetic patients with a long duration of the disease. This is based on the results reported by UKPDS [19] and in our previous findings that of 188 Type II diabetic patients who had been treated for more than 20 years in our outpatient clinic (duration : 26.0 0.4 years, onset age : 41.0 0.7 years), frequencies of insulin-treated patients at 10 years and 20 years after onset were 21.5 and 53.2 %, respectively. These frequencies are almost consistent with present findings (Fig. 2) . Thus, the effect of the genetic factor of the CC genotype on the insulin requirement could be explained with the natural course at the early stage (at 5 years) and at the late stage (at 20 years). In insulin-treated patients, the period of years from the onset to the start of insulin therapy was not significantly different between patients with the CC genotype and patients with the others (Table 4) . However, patients with a short duration and a long duration were excluded and the analysis was limited to the 54 insulin-treated patients with duration from 10 to 25 years, when a significant difference of the term was obtained (CC: n = 14, 9.50 1.09 years vs TT + TC : n = 40, 12.25 0.76 years, p = 0.023). These results suggest that the CC genotype might be a genetic marker for the exhaustion of the islet beta cells. A significantly lower daily dosage of injected insulin for patients with the CC genotype, despite the same levels of BMI (Table 4) , points to the genetic uniformity of the patients carrying the CC genotype.
Recently, a SNP associated with Type II diabetic patients in Mexican Americans and a Northern European population was reported by the method of positional cloning [20] . It has been suggested that the SNP (UCSNP43) is located in the intron of calpain-10 gene and that SNP could affect the expression of the calpain-10 [20] . The precise mechanism for the association between the T to C SNP in D68D and insulin requirements in Type II diabetes is not known at present. One reason for the association could be linkage disequilibrium between this SNP and a variant in the promoter region that influences the expression of the syntaxin 1A. The promoter region was not, however, cloned in this study because the expression of syntaxin 1A in the islet beta cells has been reported to affect the insulin secretion in GK rats [17] . It is also possible that this SNP is due to a disequilibrium of linkage with another gene located near the syntaxin 1A gene.
Genetic analysis for susceptibility genes or markers for pathogenesis of Type II diabetes is important from the point of view of intervention [21±25] . It would also be informative to clarify the genetic marker of requirements of insulin treatment that contribute to the clinical course in the Type II diabetes. From such a point of view, the SNP (D68D) in the syntaxin 1A gene could be a useful marker for predicting insulin treatment in Type II diabetic patients.
In conclusion, the SNP (D68D, T to C) in the syntaxin 1A gene correlated to onset age in Type II diabetic patients in Japanese and also to insulin requirement in the patients who had had diabetes for a longer period of time (more than 10 years). 
